E Haufe1, S Abraham2, A Heratizadeh3, I Harder4, A Zink5, E Weisshaar6, A Kleinheinz7, R von Kiedrowski8, M Worm9, M Bell10, A Wollenberg11, K Neubert12, P Staubach-Renz13, M Hilgers14, T Bieber15, I Fell16, B Homey17, I Effendy18, M Mempel19, K Schäkel20, S Beissert2, S Weidinger4, T Werfel3, J Schmitt21. 1. Zentrum für Evidenzbasierte Gesundheitsversorgung, Universitätsklinikum, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. 2. Klinik und Poliklinik für Dermatologie, Universitätsklinikum, TU Dresden, Dresden, Deutschland. 3. Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Hannover, Deutschland. 4. Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland. 5. Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Klinikum rechts der Isar, TU München, München, Deutschland. 6. Abteilung Klinische Sozialmedizin, Universitätsklinikum Heidelberg, Heidelberg, Deutschland. 7. Klinik für Dermatologie, Elbe Klinikum Buxtehude, Buxtehude, Deutschland. 8. CMSS - Company for Medical Study and Service Selters/Westerwald, Selters, Deutschland. 9. Klinik für Dermatologie, Venerologie und Allergologie, Charité Berlin, Berlin, Deutschland. 10. Dr. Magnus Bell, Thomas Kaiser, Hautärzte, Allergologie, Andernach, Deutschland. 11. Klinik und Poliklinik für Dermatologie und Allergologie, LMU München, München, Deutschland. 12. Praxis Dipl.-Med. Kathrin Neubert, Burgstädt, Deutschland. 13. Klinik für Dermatologie und Allergologie, Universitätsmedizin Mainz, Mainz, Deutschland. 14. Klinik für Dermatologie und Allergologie, Universitätsklinikum Aachen, Aachen, Deutschland. 15. Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum Bonn, Bonn, Deutschland. 16. Hautmedizin Bad Soden, Bad Soden, Deutschland. 17. Hautklinik, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland. 18. Hautklinik, Klinikum Bielefeld gem. GmbH, Bielefeld, Deutschland. 19. Hautarztpraxis Prof. Dr. med. Martin Mempel, Elmshorn, Deutschland. 20. Universitäts-Hautklinik Heidelberg, Heidelberg, Deutschland. 21. Zentrum für Evidenzbasierte Gesundheitsversorgung, Universitätsklinikum, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. Jochen.Schmitt@uniklinikum-dresden.de.
Abstract
BACKGROUND: Clinical registries may provide high-quality evidence on the use and effectiveness of therapeutic interventions under real-life conditions. Adults with moderate-to-severe atopic eczema (atopic dermatitis [AD]) are enrolled into TREATgermany and prospectively followed over at least 2 years. This paper analyses the association between dermatological quality of life and work limitations. MATERIALS AND METHODS: Treatment modalities and a broad set of physician- and patient-reported outcome measures are documented using validated instruments to assess clinical disease severity (EASI [Eczema Area and Severity Index], objective SCORAD [objective-SCORing Atopic Dermatitis]), quality of life (DLQI [Dermatology Life Quality Index]), symptoms (POEM [Patient-oriented Eczema Measure]), global disease severity, as well as patient satisfaction and work limitations including presenteeism (WLQ [Work Limitation Questionnaire]). From 06/2016 until 12/2017, 241 individuals (mean age 43 ± 15 years, 38.6% female) were enrolled at 19 recruitment centers; 69% of the patients were employed. RESULTS: Employed persons had DLQI and WLQ scores of 10.6 ± 6.9 points and 17.7 ± 18.1%, respectively. Mean presenteeism was substantial accounting for 9.2%. With coefficients of 0.39 and 0.33 WLQ and presenteeism scores significantly correlate with DLQI (p < 0.000). Bootstrapped regression models showed that the limitations in coping with work requirements increase by 1.7% as DLQI increases by one point. Lower quality of life due to AD is most strongly associated with limitations in the area of physical and performance requirements in general. Presenteeism increases by 0.5% as DLQI increases by one point. CONCLUSION: Moderate-to-severe AD has substantial adverse economic impact with mean productivity loss of patients of almost 10%. Future analyses from TREATgermany will address the impact of innovative treatment modalities on quality of life and work productivity of patients with moderate-to-severe AD.
BACKGROUND: Clinical registries may provide high-quality evidence on the use and effectiveness of therapeutic interventions under real-life conditions. Adults with moderate-to-severe atopic eczema (atopic dermatitis [AD]) are enrolled into TREATgermany and prospectively followed over at least 2 years. This paper analyses the association between dermatological quality of life and work limitations. MATERIALS AND METHODS: Treatment modalities and a broad set of physician- and patient-reported outcome measures are documented using validated instruments to assess clinical disease severity (EASI [Eczema Area and Severity Index], objective SCORAD [objective-SCORing Atopic Dermatitis]), quality of life (DLQI [Dermatology Life Quality Index]), symptoms (POEM [Patient-oriented Eczema Measure]), global disease severity, as well as patient satisfaction and work limitations including presenteeism (WLQ [Work Limitation Questionnaire]). From 06/2016 until 12/2017, 241 individuals (mean age 43 ± 15 years, 38.6% female) were enrolled at 19 recruitment centers; 69% of the patients were employed. RESULTS: Employed persons had DLQI and WLQ scores of 10.6 ± 6.9 points and 17.7 ± 18.1%, respectively. Mean presenteeism was substantial accounting for 9.2%. With coefficients of 0.39 and 0.33 WLQ and presenteeism scores significantly correlate with DLQI (p < 0.000). Bootstrapped regression models showed that the limitations in coping with work requirements increase by 1.7% as DLQI increases by one point. Lower quality of life due to AD is most strongly associated with limitations in the area of physical and performance requirements in general. Presenteeism increases by 0.5% as DLQI increases by one point. CONCLUSION: Moderate-to-severe AD has substantial adverse economic impact with mean productivity loss of patients of almost 10%. Future analyses from TREATgermany will address the impact of innovative treatment modalities on quality of life and work productivity of patients with moderate-to-severe AD.
Entities:
Keywords:
Benefit; Costs; Evidence-based medicine; Health care; Health economy
Authors: P I Spuls; L A A Gerbens; E Simpson; C J Apfelbacher; J R Chalmers; K S Thomas; C A C Prinsen; L B von Kobyletzki; J A Singh; H C Williams; J Schmitt Journal: Br J Dermatol Date: 2017-03-02 Impact factor: 9.302
Authors: Andrew Blauvelt; Marjolein de Bruin-Weller; Melinda Gooderham; Jennifer C Cather; Jamie Weisman; David Pariser; Eric L Simpson; Kim A Papp; H Chih-Ho Hong; Diana Rubel; Peter Foley; Errol Prens; Christopher E M Griffiths; Takafumi Etoh; Pedro Herranz Pinto; Ramon M Pujol; Jacek C Szepietowski; Karel Ettler; Lajos Kemény; Xiaoping Zhu; Bolanle Akinlade; Thomas Hultsch; Vera Mastey; Abhijit Gadkari; Laurent Eckert; Nikhil Amin; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos; Brad Shumel Journal: Lancet Date: 2017-05-04 Impact factor: 79.321
Authors: A Langenbruch; N Mohr; F Abeck; J Schmitt; S Ständer; T Werfel; D Thaçi; S Weidinger; M Augustin Journal: Hautarzt Date: 2021-09-20 Impact factor: 0.751